Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) is scheduled to announce its earnings results before the market opens on Tuesday, November 7th.
Trimel Pharmaceuticals Corp. (TRLPF) opened at $0.09 on Friday. Trimel Pharmaceuticals Corp. has a 12-month low of $0.08 and a 12-month high of $0.13. The company has a quick ratio of 0.94, a current ratio of 1.81 and a debt-to-equity ratio of 0.20.
Separately, ValuEngine upgraded Trimel Pharmaceuticals Corp. from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th.
COPYRIGHT VIOLATION WARNING: “Trimel Pharmaceuticals Corp. (TRLPF) to Release Quarterly Earnings on Tuesday” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/05/trimel-pharmaceuticals-corp-trlpf-to-release-quarterly-earnings-on-tuesday.html.
About Trimel Pharmaceuticals Corp.
Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.
What are top analysts saying about Trimel Pharmaceuticals Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trimel Pharmaceuticals Corp. and related companies.